Fast-acting insulin aspart
PreclinicalSmall molecule
Novo NordiskFast-acting insulin aspart is one of 2 small molecule programs targeting Sudden Sensorineural Hearing Loss (SSNHL). It is currently in Preclinical.
1
Indications
7
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in Sudden Sensorineural Hearing Loss (SSNHL)
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Type 1 Diabetes3 trials
Type 1 Diabetes Mellitus1 trial
Sudden Sensorineural Hearing Loss (SSNHL)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Fast-acting insulin aspart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company